Showing results (1-10 of 5) with videos related to
Sort By:
Pageof 1
Expert Opinion on Drug Safety|May 9, 2008
Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agentsNenad Sarapa, Margaret R BrittoEuropean Journal of Clinical Pharmacology|May 12, 2005
The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitorNenad Sarapa, Margaret R Britto, Michelle B Mainka, et al.Clinical Therapeutics|December 28, 2002
The pharmacokinetics of sumatriptan when administered with norethindrone 1 mg/ethinyl estradiol 0.035 mg in healthy volunteersKaty H P Moore, Scott McNeal, Margaret R Britto, et al.Cancer Chemotherapy and Pharmacology|August 9, 2003
Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinomaNenad Sarapa, Margaret R Britto, William Speed, et al.Journal of Clinical Pharmacology|September 16, 2003
Valdecoxib, a COX-2-specific inhibitor, does not affect cardiac repolarizationNenad Sarapa, Margaret R Britto, Barbara Cotton, et al.Pageof 1